Research programme: antiviral therapeutics - Aphios

Drug Profile

Research programme: antiviral therapeutics - Aphios

Alternative Names: Albasomes; APP-0303; APP-0401; Betulinic acid - Aphios; Hypericin - Aphios

Latest Information Update: 22 Jun 2009

Price : $50

At a glance

  • Originator Aphios Corporation
  • Class
  • Mechanism of Action HIV replication inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections
  • Research Smallpox

Most Recent Events

  • 20 May 2009 Early research in Smallpox in USA (unspecified route)
  • 27 Mar 2009 Preclinical development for HIV infections is ongoing
  • 26 Mar 2004 Preclinical trials in HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top